217 related articles for article (PubMed ID: 38159229)
21. Impact of inhibitors and L2 antibodies upon the infectivity of diverse alpha and beta human papillomavirus types.
Kwak K; Jiang R; Wang JW; Jagu S; Kirnbauer R; Roden RB
PLoS One; 2014; 9(5):e97232. PubMed ID: 24816794
[TBL] [Abstract][Full Text] [Related]
22. Susceptibility of various human tissues to transformation in vivo with human papillomavirus type 11.
Kreider JW; Howett MK; Stoler MH; Zaino RJ; Welsh P
Int J Cancer; 1987 Apr; 39(4):459-65. PubMed ID: 3030939
[TBL] [Abstract][Full Text] [Related]
23. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.
Jagu S; Karanam B; Gambhira R; Chivukula SV; Chaganti RJ; Lowy DR; Schiller JT; Roden RB
J Natl Cancer Inst; 2009 Jun; 101(11):782-92. PubMed ID: 19470949
[TBL] [Abstract][Full Text] [Related]
24. Genitoanal human papillomavirus infection and associated neoplasias.
Gross G
Curr Probl Dermatol; 2014; 45():98-122. PubMed ID: 24643181
[TBL] [Abstract][Full Text] [Related]
25. The human papillomavirus vaccines.
Ljubojević S
Acta Dermatovenerol Croat; 2006; 14(3):208. PubMed ID: 17010274
[TBL] [Abstract][Full Text] [Related]
26. Chapter 1: HPV in the etiology of human cancer.
Muñoz N; Castellsagué X; Berrington de González A; Gissmann L
Vaccine; 2006 Aug; 24 Suppl 3():S3/1-10. PubMed ID: 16949995
[TBL] [Abstract][Full Text] [Related]
27. Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer.
Zhai L; Yadav R; Kunda NK; Anderson D; Bruckner E; Miller EK; Basu R; Muttil P; Tumban E
Antiviral Res; 2019 Jun; 166():56-65. PubMed ID: 30926288
[TBL] [Abstract][Full Text] [Related]
28. Human Papillomavirus-related Cancers and Mitochondria.
Cruz-Gregorio A; Aranda-Rivera AK; Pedraza-Chaverri J
Virus Res; 2020 Sep; 286():198016. PubMed ID: 32445871
[TBL] [Abstract][Full Text] [Related]
29. Crystal Structures of Plk1 Polo-Box Domain Bound to the Human Papillomavirus Minor Capsid Protein L2-Derived Peptide.
Jung S; Lee HS; Shin HC; Choi JS; Kim SJ; Ku B
J Microbiol; 2023 Aug; 61(8):755-764. PubMed ID: 37684534
[TBL] [Abstract][Full Text] [Related]
30. Lipid metabolism and oxidative stress in HPV-related cancers.
Cruz-Gregorio A; Aranda-Rivera AK; Ortega-Lozano AJ; Pedraza-Chaverri J; Mendoza-Hoffmann F
Free Radic Biol Med; 2021 Aug; 172():226-236. PubMed ID: 34129929
[TBL] [Abstract][Full Text] [Related]
31. Nuclear factor erythroid 2-related factor 2 in human papillomavirus-related cancers.
Cruz-Gregorio A; Aranda-Rivera AK; Pedraza-Chaverri J
Rev Med Virol; 2022 May; 32(3):e2308. PubMed ID: 34694662
[TBL] [Abstract][Full Text] [Related]
32. Establishment of human papillomavirus infection requires cell cycle progression.
Pyeon D; Pearce SM; Lank SM; Ahlquist P; Lambert PF
PLoS Pathog; 2009 Feb; 5(2):e1000318. PubMed ID: 19247434
[TBL] [Abstract][Full Text] [Related]
33. Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity.
Hebner CM; Laimins LA
Rev Med Virol; 2006; 16(2):83-97. PubMed ID: 16287204
[TBL] [Abstract][Full Text] [Related]
34. Developments in L2-based human papillomavirus (HPV) vaccines.
Schellenbacher C; Roden RBS; Kirnbauer R
Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
[TBL] [Abstract][Full Text] [Related]
35. Characterization of Mus musculus papillomavirus 1 infection in situ reveals an unusual pattern of late gene expression and capsid protein localization.
Handisurya A; Day PM; Thompson CD; Buck CB; Pang YY; Lowy DR; Schiller JT
J Virol; 2013 Dec; 87(24):13214-25. PubMed ID: 24067981
[TBL] [Abstract][Full Text] [Related]
36. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
Pouyanfard S; Spagnoli G; Bulli L; Balz K; Yang F; Odenwald C; Seitz H; Mariz FC; Bolchi A; Ottonello S; Müller M
J Virol; 2018 Feb; 92(4):. PubMed ID: 29212932
[TBL] [Abstract][Full Text] [Related]
37. L2, the minor capsid protein of papillomavirus.
Wang JW; Roden RB
Virology; 2013 Oct; 445(1-2):175-86. PubMed ID: 23689062
[TBL] [Abstract][Full Text] [Related]
38. Potential Effects of Human Papillomavirus Type Substitution, Superinfection Exclusion and Latency on the Efficacy of the Current L1 Prophylactic Vaccines.
Hampson IN; Oliver AW; Hampson L
Viruses; 2020 Dec; 13(1):. PubMed ID: 33374445
[TBL] [Abstract][Full Text] [Related]
39. Frequency of human papillomavirus types 16, 18, 31, and 33 and sites of cervical lesions in gynecological patients from Recife, Brazil.
Baldez da Silva MF; Guimarães V; Silva MA; Medeiros do Amaral CM; Beçak W; Stocco RC; Freitas AC; Crovella S
Genet Mol Res; 2012 Mar; 11(1):462-6. PubMed ID: 22427039
[TBL] [Abstract][Full Text] [Related]
40. The features of high-risk human papillomavirus infection in different female genital sites and impacts on HPV-based cervical cancer screening.
Li T; Chen S; Li X; Wu Z; Zhao Y; Cui J; Liu B; Chen F; Zhang X; Qiao Y; Chen W
Virol J; 2023 Jun; 20(1):116. PubMed ID: 37280665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
